RedHill Biopharma Ltd. (RDHL) said Wednesday that the U.S. Food and Drug Administration or FDA has granted Fast Track designation to RHB-204 for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC). This is a rare disease for which there is no FDA-approved first-line therapy.
The FDA's Fast Track designation is intended to help progress development and speed up the review of novel therapies for serious conditions for which there is an unmet medical need.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.